Literature DB >> 19270644

Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands.

Colin J R Stewart1, Maxine L Crook, Yee C Leung, Michael Platten.   

Abstract

Endometrial adenocarcinomas may show a distinctive pattern of invasion characterized by the presence of microcystic, elongated and fragmented glands, often most evident along the advancing tumor margin. Earlier, we have shown that these changes appear restricted to low-grade endometrioid carcinomas, many of which show focal mucinous differentiation and lymphovascular space invasion. However, the molecular alterations associated with this morphological alteration are not known. In this study, we have examined immunoreactivity for the cell cycle regulatory proteins cyclin D1, p16 and beta-catenin in 22 endometrial carcinomas, specifically comparing the results in conventional tumor areas and in foci in which the glands exhibited microcystic, elongated and fragmented appearances. The conventional neoplastic glands exhibited cyclin D1 and p16 expression in most cases, with >50% tumor cells positive in 8 cases and 11 tumors, respectively. Membranous expression of beta-catenin was usually preserved, with variable cytoplasmic and nuclear staining. Cyclin D1 and beta-catenin predominantly stained cells at the peripheral or basal aspect of the conventional glands, whereas p16 was more uniformly expressed centrally. Tumor foci composed of microcystic, fragmented and elongated glands showed strong expression of cyclin D1 and p16, sometimes in contrast to unstained contiguous or adjacent conventional neoplastic elements, and there was also loss or fragmentation of membranous beta-catenin staining. Intravascular tumor cells also expressed cyclin D1 and p16 and therefore the immunostains often highlighted subtle foci of lymphovascular invasion. The heterogeneous expression of cell cycle regulatory proteins within endometrial adenocarcinoma illustrates the importance of assessing microanatomical variations in immunoreactivity, particularly at the advancing margin of tumors. The upregulation of cyclin D1 and p16, together with loss of membranous beta-catenin expression in microcystic, fragmented and elongated glands, is similar to epithelial-mesenchymal transitions observed in other malignancies and suggests that this pattern of invasion represents an active rather than a degenerative cellular process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270644     DOI: 10.1038/modpathol.2009.33

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

Review 1.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

2.  Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.

Authors:  L Wang; L Sun; J Huang; M Jiang
Journal:  Cell Prolif       Date:  2011-06       Impact factor: 6.831

3.  Comparison of beta-catenin with TGF-beta1, HIF-1alpha and patients' disease-free survival in human colorectal cancer.

Authors:  Andrzej Wincewicz; Mariusz Koda; Stanislaw Sulkowski; Luiza Kanczuga-Koda; Mariola Sulkowska
Journal:  Pathol Oncol Res       Date:  2009-11-08       Impact factor: 3.201

4.  Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma.

Authors:  Banu Dogan Gun; Burak Bahadir; Sibel Bektas; Figen Barut; Gamze Yurdakan; Nilufer Onak Kandemir; Sukru Oguz Ozdamar
Journal:  Diagn Pathol       Date:  2012-07-11       Impact factor: 2.644

5.  Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features.

Authors:  Karuna Sangwan; Monika Garg; Nayana Pathak; Lavleen Bharti
Journal:  J Lab Physicians       Date:  2020-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.